why choose us

First received: September 22, 2023

Clinical Trial: Optimization of OnabotulinumtoxinA (BTX-A) Injection for the Treatment of Neurogenic Lower Urinary Tract Dysfunction

Study Status: Completed

Recruit Status: RECRUITING

Condition: Neurogenic Bladder

Study Type: INTERVENTIONAL


Official Title: Optimization of OnabotulinumtoxinA (BTX-A) Injection for the Treatment of Neurogenic Lower Urinary Tract Dysfunction

Brief Summary: The purpose of this study is to evaluate and standardize the way providers perform OnabotulinumtoxinA (BTX-A) injections into the bladder for the diagnosis of neurogenic lower urinary tract dysfunction (NLUTD)/overactive bladder (OAB).NLUTD/OAB is a syndrome that affects many people, and includes urinary frequency, urinary urgency, urgency incontinence, and nocturia.This syndrome can be challenging to treat and often requires procedural management - including BTX-A injections into the bladder.

Read more